December 12, 2019

To,
BSE Ltd / NSE Ltd

Dear Sirs / Madam,

EIR Report Received for US FDA Inspection of Pharmaceutical Facility at Panoli, Gujarat with 'Zero' 483 observations

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the company's pharmaceutical manufacturing facility located at Panoli, Gujarat, was recently inspected by the U.S. Food and Drug Administration (US FDA) in compliance with their requirements.

The five-day detailed inspection was carried out during the period September 9th - 13th, 2019. The inspection confirmed the site to be compliant with the principles and guidelines of Current Good Manufacturing Practices (CGMP).

The inspection concluded with 'Zero' 483 observations from the Auditors. The Establishment Inspection Report (EIR) received on December 12th, 2019 has classified the facility under NAI (No Action Indicated) for CGMP compliance.

Hikal Ltd.

Company Secretary